Shares of Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $59.29, but opened at $63.25. Basilea Pharmaceutica shares last traded at $63.25, with a volume of 200 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, Zacks Research upgraded Basilea Pharmaceutica to a “hold” rating in a research note on Wednesday, September 24th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.
Read Our Latest Stock Report on Basilea Pharmaceutica
Basilea Pharmaceutica Stock Up 6.7%
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Read More
- Five stocks we like better than Basilea Pharmaceutica
- Quiet Period Expirations Explained
- Investors Were Dead Wrong About Box—This AI-Driven Comeback Just Proved It
- What is the S&P 500 and How It is Distinct from Other Indexes
- Can Alibaba’s Big Bets Pay Off After a Breakout Year?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- How Accenture’s OpenAI Partnership Turns AI Hype Into Profits
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
